Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.4462
USD
|
-7.02%
|
|
-11.75%
|
-68.35%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
292.7
|
76.51
|
162.5
|
53.25
|
-
|
Enterprise Value (EV)
1 |
235.9
|
76.51
|
162.5
|
123.2
|
87.95
|
P/E ratio
|
-
|
-0.28
x
|
-2.24
x
|
-1.27
x
|
-1.44
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.46
x
|
0.07
x
|
0.13
x
|
0.04
x
|
0.03
x
|
EV / Revenue
|
0.37
x
|
0.07
x
|
0.13
x
|
0.08
x
|
0.05
x
|
EV / EBITDA
|
-2.47
x
|
-0.6
x
|
-1.9
x
|
107
x
|
6.03
x
|
EV / FCF
|
-
|
-0.57
x
|
-
|
6.73
x
|
2.29
x
|
FCF Yield
|
-
|
-175%
|
-
|
14.8%
|
43.7%
|
Price to Book
|
-
|
-
|
-
|
0.42
x
|
0.47
x
|
Nbr of stocks (in thousands)
|
41,579
|
41,579
|
115,242
|
119,334
|
-
|
Reference price
2 |
7.040
|
1.840
|
1.410
|
0.4462
|
0.4462
|
Announcement Date
|
10/21/22
|
3/31/23
|
3/28/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
637.4
|
1,050
|
1,266
|
1,494
|
1,739
|
EBITDA
1 |
-
|
-95.49
|
-127.9
|
-85.5
|
1.15
|
14.59
|
EBIT
1 |
-
|
-187.9
|
-1,561
|
-167.9
|
-92.05
|
-84.04
|
Operating Margin
|
-
|
-29.49%
|
-148.73%
|
-13.26%
|
-6.16%
|
-4.83%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-1,560
|
-183.7
|
-111.2
|
-101.3
|
Net income
1 |
-41.07
|
-
|
-270.1
|
-57.77
|
-59.98
|
-61.29
|
Net margin
|
-
|
-
|
-25.74%
|
-4.56%
|
-4.02%
|
-3.53%
|
EPS
2 |
-0.6200
|
-
|
-6.500
|
-0.6300
|
-0.3500
|
-0.3100
|
Free Cash Flow
1 |
-
|
-
|
-133.8
|
-
|
18.3
|
38.4
|
FCF margin
|
-
|
-
|
-12.74%
|
-
|
1.23%
|
2.21%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
1,591.3%
|
263.14%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/12/21
|
10/21/22
|
3/31/23
|
3/28/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
177.9
|
273.5
|
269.5
|
248.3
|
258.2
|
302.1
|
329.1
|
288.4
|
346.9
|
357.2
|
369
|
367.7
|
400
|
425.7
|
EBITDA
1 |
-
|
-43.05
|
-18.93
|
-28.6
|
-40.31
|
-40.1
|
-19.13
|
0.217
|
-22.33
|
-44.26
|
-17.77
|
-7.458
|
8.83
|
14.22
|
6.1
|
EBIT
1 |
-
|
-127.4
|
-52.17
|
-912.2
|
-60.01
|
-536.5
|
-48.82
|
-21.03
|
-33.82
|
-64.26
|
-37.48
|
-31.47
|
-14.9
|
-8.238
|
-
|
Operating Margin
|
-
|
-71.63%
|
-19.07%
|
-338.53%
|
-24.17%
|
-207.78%
|
-16.16%
|
-6.39%
|
-11.73%
|
-18.53%
|
-10.49%
|
-8.53%
|
-4.05%
|
-2.06%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-
|
-65.33
|
-530.5
|
-52.16
|
-27.36
|
-36.88
|
-67.34
|
-44.69
|
-36.29
|
-17.39
|
-13.12
|
-
|
Net income
1 |
-31.37
|
-
|
-
|
-
|
-11.17
|
-94
|
-9.199
|
-9.816
|
-13.3
|
-25.46
|
-22.33
|
-17.52
|
-15.88
|
-9.888
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-4.5%
|
-36.41%
|
-3.05%
|
-2.98%
|
-4.61%
|
-7.34%
|
-6.25%
|
-4.75%
|
-4.32%
|
-2.47%
|
-
|
EPS
2 |
-0.4500
|
-
|
-
|
-
|
-0.2700
|
-2.260
|
-0.2200
|
-0.0900
|
-0.1200
|
-0.2200
|
-0.1275
|
-0.1050
|
-0.0900
|
-0.0575
|
-0.1600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/9/21
|
10/21/22
|
10/21/22
|
10/20/22
|
11/14/22
|
3/31/23
|
5/10/23
|
8/7/23
|
11/8/23
|
3/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
70
|
34.7
|
Net Cash position
1 |
-
|
56.9
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
60.87
x
|
2.378
x
|
Free Cash Flow
1 |
-
|
-
|
-134
|
-
|
18.3
|
38.4
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
-
|
1.050
|
0.9400
|
Cash Flow per Share
2 |
-
|
-1.680
|
-3.030
|
-
|
0.1900
|
0.3700
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/12/21
|
10/21/22
|
3/31/23
|
3/28/24
|
-
|
-
|
Last Close Price
0.4462
USD Average target price
2.7
USD Spread / Average Target +505.11% Consensus |
1st Jan change
|
Capi.
|
---|
| -68.35% | 53.25M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|